ILiAD Biotechnologies Closes $42.8M Series D Financing

The round was led by Knott Partners. The company intends to use the funds to conduct a Phase 2b Human Challenge study to determine if vaccination with BPZE1 prevents colonization from wild-type Bordetella pertussis infection. In addition to funding continued operations, R&D and manufacturing development of BPZE1, the financing will support further clinical studies of the vaccine.

Led by Keith Rubin, MD, Founder and Chief Executive Officer, ILiAD Biotechnologies is a clinical stage biotechnology company dedicated to the prevention and treatment of human disease caused by Bordetella pertussis. BPZE1 is the most advanced next generation pertussis vaccine, designed to overcome deficiencies of current vaccines, including limited durability and the inability to prevent nasopharyngeal Bordetella pertussis infections that lead to transmission, especially to vulnerable infants. BPZE1 has completed four human clinical studies and at the end of 2021, the FDA provided BPZE1 with Fast Track designation. BPZE1 was developed by Camille Locht, PhD and Nathalie Mielcarek, PhD at the Institut Pasteur de Lille and French National Institute of Health and Medical Research. ILiAD holds exclusive global rights to BPZE1 and related B-Tech™ technologies that are covered by 62 issued patents. An additional 31 patents are pending globally.06/09/2022